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Thepresentpaperdescribesthepossibleconnectionbetweenalcoholconsumptionandadherencetomedicineusedtotreathuman
deﬁciency viral (HIV) infection. Highly active antiretroviral therapy (HAART) has a positive inﬂuence on longevity in patients
with HIV, substantially reducing morbidity and mortality, including resource-poor settings such as South Africa. However, in a
systematic comparison of HAART outcomes between low-income and high-income countries in the treatment of HIV-patients,
mortality was higher in resource-poor settings. Speciﬁcally, in South Africa, patients often suﬀer from concomitant tuberculosis
and other infections that may contribute to these results. Alcohol inﬂuences the use of medicine for opportunistic infections
(e.g., pneumonia, tuberculosis), or coinfections HIV-hepatitis viruses-B (HBV) and C (HCV), cytomegalovirus, or herpes simplex
virus. Furthermore, alcohol use may negatively impact on medication adherence contributing to HIV progression. The materials
used provide a data-supported approach. They are based on analysis of published (2006–2011) world literature and the experience
of the authors in the speciﬁed topic. Intended for use by health care professionals, these recommendations suggest approaches
to the therapeutic and preventive aspects of care. Our intention was to fully characterize the quality of evidence supporting
recommendations, which are reﬂecting beneﬁt versus risk, and assessing strength or certainty.
1.Introduction
Failure to recognize alcohol behaviour remains a signif-
i c a n tp r o b l e mt h a ti m p a i r se ﬀorts directed towards the
prevention and management of patients with alcoholic liver
damage. Although there are limitations in the available data,
the World Health Organization’s Global Alcohol database,
which has been in existence since 1996, has been used to
estimate worldwide patterns of alcohol consumption, and
it allows comparisons of alcohol-related morbidity and
mortality. The burden of alcohol-related disease is highest
in the developing world, including South Africa. Pithey
and Parry [1] describe the association between alcohol use
and human immunodeﬁciency virus (HIV) infection in
a systematic review of sub-Saharan African studies. The
authors present studies that have quantiﬁed the association
between alcohol consumption and HIV infection in this
region. They analyzed work performed between 2000 and
2008 that reported relative measures of the association
between alcohol use and HIV prevalence and/or serocon-
version rates. However, the authors sustain that in order to
conﬁrm causality, the use of clearly deﬁned standardised
measures of alcohol use is needed [1]. Patterns of alco-
hol consumption are expressed and regulated diﬀerently
in diverse geographical regions. There are contradictory2 AIDS Research and Treatment
drinking guidelines deﬁning low-risk and high-risk drink-
ing in diﬀerent countries. In the United States of Amer-
ica, the National Institute of Alcohol and Alcohol Abuse
(NIAAA) and the United States Department of Agriculture
deﬁne low risk drinking as ≤14 drinks/week and ≤4
drinks on any day for men. For women, the deﬁnition
of low risk drinking is ≤7 drinks/week or ≤3 drinks
on any day (http://www.rethinkingdrinking.niaaa.nih.gov/;
http://www.cnpp.usda.gov/dgas2010-dgacreport.htm). Pro-
posed guidelines speciﬁc for each nation make it diﬃcult to
conduct an international generalization of “moderate, low-
risk drinking” versus “high-risk drinking.”
2.MaterialandMethods
We performed a systematic review of published PubMed
literature, searching for articles that contained information
about “alcohol”, “HIV” and “antiretroviral therapy” pub-
lished between January 2006 and June 2011. We did not
limit our search to literature published in English. We found
over 365 results using the key words “alcohol,” “adherence,”
“ART” and “HIV,” from which we selected 230 articles that
we analyzed.
From these initial results, we selected 25 articles to be
included in the “disease progression” sections and 38 articles
to be included in the “adherence” section. Particular atten-
tion was placed on those papers that provided an indication
of the type and the amount of alcohol consumed. In order
to obtain more focused results so that we could, where
necessary, refer to South Africa, we also included the words
“South Africa” in the search. However, we did not have
“South Africa” as an exclusion criterion. Main reasons for
excluding articles include poor characterization of alcohol
consumption patterns, incomplete or poor characterization
of adherence to medication or/and disease progression,
in vitro or in vivo animal studies, and studies where the
focus was on comorbid diseases and addictions, as well as
treatments for these conditions, whose eﬀects could have
undermined that of alcohol (e.g., environmental habits
(drugsofabuse,smoking),viralinfections(cytomegalovirus,
herpes simplex virus, hepatitis C, hepatitis B), malaria,
tuberculosis).
Althoughnotspeciﬁcforthemaintopicsdiscussed,some
relevant papers published prior to 2006 contained important
information that was used to reinforce our arguments and
were therefore discussed as well.
Figure 1 illustrates the methods used for the literature
search and the number of articles chosen for diﬀerent
subjects. Data accessible in this paper are descriptive in
nature. All prevalence estimates of alcohol use are the data
presented by their respective authors.
3. Results andDiscussion
3.1. HIV and Alcohol Misuse. Rehm and Parry [2]d e s c r i b e d
the link between alcohol consumption and infectious dis-
eases in South Africa. Alcohol abuse is often associated
with numerous facets of HIV disease progression, ranging
from hepatotoxicity to immune system impairment. Table 1
PubMedsearch
“alcohol HAART”
365 results prior to July 2011
230 articles published mostly between January 2006 and July 2011 were 
downloaded and read
25 articles were included in the disease 
progression section 
38 articles were included in the 
adherence section (Table 3) (Tables 1 and 2)
Figure 1: Methods used for literature search.
presents the role played by alcohol on the progression of
HIV-associated disease symptoms.
Neuman et al. [3], N´ u˜ nez [4], and Barve et al. [5]e x t e n -
sively reviewed hepatotoxicity associated with alcohol use
and highly active antiretroviral therapy (HAART) admin-
istration. The development of lung infection was reviewed
by Rehm et al. [6] and Quintero and Guidot [7], while the
progress of cardiovascular diseases was reviewed by Freiberg
andKraemer[8].Rosenbloometal.[9]revieweddetrimental
eﬀects on the structure, chemistry, and function of the cen-
tral nervous system.
Neuman et al. [3] discuss the interactions between thera-
peutic drugs used to minimize and control drug and alcohol
dependence. Furthermore, drug-drug interactions occur
between HAART and alcohol, diﬀerent HAART components
and methadone, or each one of the therapies with the
other, thus contributing to a higher toxicity level. With the
evolution of eﬀective antiretroviral therapy (ART), survival
of persons living with HIV and acquired immunodeﬁciency
syndrome (AIDS) has increased dramatically, leading to
more interactions with other liver related comorbidities such
asalcoholandviralhepatitisandthedrugsusedtotreatthese
diseases.
The following section will review several studies that
analyzed the relationship between alcohol misuse and HIV
disease progression. Two important laboratory determinants
of the rate of disease progression are the CD4+ cell counts
and the plasma viral load.
3.1.1. Role of Hepatitis Viruses on HIV. Hazardous drinking
is often associated with liver disease [10, 11], particularly
among hepatitis C virus (HCV) monoinfected patients
and HIV/HCV coinfected patients [12]. Several interesting
trends were observed in the MORTAVIC study, a multi-
centre prospective cross-sectional survey of French hospital
departments of internal medicine and infectious diseases
participating in the treatment of HIV-infected individuals
[13, 14]. From 215 deaths that occurred in 2003 among
20940 HIV positive, 27 (12.6%) can be attributed to end-
stage liver disease. Of these, HCV coinfection was present
in 25 (92.6%) patients, alcohol consumption of any kind
in 25 (92.6%) patients, moderate alcohol consumption
(30–60g/day) in 12 (44.4%) patients, and heavy alcohol
consumption (>60g/day) in 7 (26.0%) patients [13]. Over
the previous decade, the proportion of patients dying fromAIDS Research and Treatment 3
Table 1: Interactions between Alcohol and HIV Disease Progression.
Ref. Study
settings Population characteristics Alcohol use patterns Main ﬁndings
Found an Association
[11] USA 696 HIV positive patients
10.4% reported hazardous drinking (>14
drinks/week or >4 drinks/occasion for
men and >7 drinks/week or >3
drinks/occasion for women)
Hazardous drinking associated with liver
disease, deﬁned as aspartate
aminotransferase to platelet ratio index
>1.5 (RR 3.72, 95% CI 1.40–9.87)
[12]I t a l y
190 patients (71 HIV monoinfected,
53 HCV monoinfected and 66
HIV/HCV coinfected)
The extent of advanced liver ﬁbrosis,
deﬁned as liver stiﬀness ≥9.5kPa, correlate
with alcohol intake (nonsigniﬁcant in HIV
monoinfected patients, P<0.001 in HCV
monoinfected patients and P<0.04 in
HIV/HCV coinfected patients), but not
with HAART exposure or duration of
HAART
[13] France 20940 HIV positive patients
Alcohol consumption of any kind in 25
(92.6%) of 27 patients who died from
end-stage liver disease
Proportion of excessive alcohol
consumption higher in 2003 compared to
1995 (P<0.05)
[14] France 24000 HIV positive patients
Excessive alcohol consumption
(>30g/day) reported in 23 (47.9%) of 48
patients who died from end-stage lived
disease
The combination of alcohol and HCV
coinfection led 12 (25.0%) deaths
Consuming alcohol in excess of 30g/day
associated with death due to end-stage
liver disease (P = 0.005)
[15] France
210 HIV positive patients with a
history of injectable drug use or
HCV (60 HIV positive and 150
HIV-negative).
There were 41 (19.5%) cases of liver
cirrhosis
76 patients suﬀered from excessive
drinking, with similar rate between HIV
positive individuals and HIV-negative
individuals
HIV positivity (OR 2.2, CI 1.1–4.5) and
excessive drinking (OR 1.9, CI 1.0–3.9)
independently associated with cirrhosis
[16] Spain
2168 HIV positive patients,
including 181 (8.3%) cases of
cirrhosis
95 (52.5%) cirrhotic patients admitted
current or past alcohol abuse
Alcohol consumption associated with
cirrhosis (OR 3.5, 95% CI 2.5–4.8,
P<0.01)
[17] Spain
91 HIV positive patients 30 (33.0%)
patients suﬀered from liver toxicity
10 (11.0%) patients suﬀered from
severe liver toxicity
43 (47.2%) patients coinfected with
HCV and/or HBV
High alcohol consumption risk factor for
liver toxicity (OR 3.35, 95% CI 2.43–4.62,
P = 0.01)
[20] USA 164 HIV positive patients Patients consumed alcohol 88 (53.6%)
were hazardous drinkers
Hazardous drinking associated with
worsening of dyslipidemia (OR 3.18, 95%
CI 0.99–12.05, P = 0.04)
[21]U S A
300 HIV positive patients,
82 (27.3%) patients experienced
pneumonia
60% of sample reported prior or current
alcohol abuse
Alcohol use independent predictor for
pneumonia in HIV positive smokers
(P = 0.004)
[22] Spain 122 HIV-infected adults
Alcohol abuse independent predictor for
bacteremic pneumococcal disease (OR
5.28)
[23] Spain 25 HIV-1-postive patients with
cerebrovascular ischemia
Cerebrovascular ischemia associated with
history of high alcohol intake (OR 7.13,
95% CI 1.69–30.11, P = 0.007)
[25]U S A
72 HIV-negative light/nondrinkers,
70 HIV positive light/nondrinkers,
70 HIV positive heavy drinkers and
56 HIV-negative heavy drinkers
142 (53.0%) light/nondrinkers
126 (47.0%) heavy drinkers
Synergistic interaction between alcohol
abuse and HIV infection with respect to
motor and visuomotor speed4 AIDS Research and Treatment
Table 1: Continued.
Ref. Study
settings Population characteristics Alcohol use patterns Main ﬁndings
[26]U S A
31 male HIV positive patients, 27
patients with alcoholism, 43
patients with HIV infection and
alcoholism comorbidity, and 22
normal healthy controls
70 (56.9%) patients with alcoholism
HIV and alcoholism comorbidity impair
upper motor limb to a greater degree that
HIV alone (P = 0.068) or alcoholism alone
(P = 0.062)
[27]U S A
40 HIV positive patients, 38
alcoholic patients, 47 alcoholic HIV
positive patients, and 39 controls
85 (51.8%) patients with alcoholism
Immediate episodic memory impaired in
HIV positive patients with alcoholism
comorbidity
Did Not Find an Association
[24]U S A
1539 HIV positive patients
881 (57.2%) reported
HIV-associated sensory neuropathy,
of which 335 (38.0%) reported
neuropathic pain
845 (54.9%) had a history of alcohol
abuse or dependence
History of alcohol abuse or dependence
not associated with neuropathic pain
caused by HIV-associated sensory
neuropathy
[28]I t a l y
76 HIV positive patients with
bacterial community-acquired
pneumonia 32 (42.1%) were
receiving ART
25 (32.9%) alcohol abusers Alcohol abuse not associated with a longer
time before clinical stability was achieved
[29]U S A
299 HIV positive patients.
Abnormal liver test results observed
in 80 (26.8%) patients
Amount of alcohol consumed per week or
alcohol overuse not predictors of liver test
abnormalities
[30] France 1175 HIV-infected patients
1048 (89.2%) were HCV coinfected
Alcohol consumption not associated with
HCV-related serious adverse reactions
AIDS decreased and the number of patients dying from end-
stage liver disease remained relatively constant. In recent
times, the proportion of patients dying from end-stage
liver disease is signiﬁcantly higher (21 out of 1426 deaths
(1.5%) in 1995 versus 27 out of 215 (12.6%) deaths in
2003, P<0.01). Among patients dying from end-stage liver
disease, the proportion of patients with HCV coinfection
alone and the proportion of excessive alcohol consump-
tion were signiﬁcantly higher in 2003 compared to 1995
[13].
From 287 deaths that occurred in 2005 among 24000
HIV positive patients followed at multiple centers in France,
48 (16.7%) can be attributed to end-stage liver disease
[14]. Of these, hepatitis virus coinfection was present in
45 (93.8%) patients, with 38 (79.2%) patients suﬀering
from HCV coinfection. Excessive alcohol consumption
(>30g/day) was reported by 23 (47.9%) patients in this
subsequent study [14]. Alcohol consumption was related
to death in 4 HCV/HIV coinfected patients (10.5%), while
HCV coinfection led to an additional 8 deaths (21.0%) in
HIV positive patients who abused alcohol, as assessed by the
patients’physicians.Anadditionalcaseoflethalcirrhosiswas
identiﬁed independent of alcohol consumption or viral hep-
atitiscoinfection[14].Overall,36(75.0%)patientsdiedfrom
cirrhosis, 7 (14.6%) patients died from HCV coinfection
and 5 (10.4%) patients died from hepatitis B virus (HBV)
coinfection. Hepatitis virus coinfection (P<0.001) and
consumingalcoholinexcessof30g/day(P = 0.005)weresig-
niﬁcantly associated with death due to end-stage liver disease
[14].
3.1.2. Role of Cirrhosis in Disease Progression. While both
HIV positivity and excessive drinking were independently
associated with cirrhosis, the proportion of patients with
cirrhosis was higher in HIV positive individuals (18/60,
30.0%), compared to HIV-negative individuals (23/150,
15.3%) (P<0.0001) in another French study [15]. There
were no diﬀerences in the incidence of cirrhosis between
HIV positive excessive drinkers and HIV-negative excessive
drinkers. This should be interpreted with care, as the low
number of patients included in this study, particularly HIV
positive patients, could prevent the identiﬁcation of an
interaction between HIV positivity and excessive drinking
with respect to the development of cirrhosis [15].
Among 181 cases of liver cirrhosis in a large sample of
2168 HIV positive patients, 149 (82.3%) were caused by
HCV, 3 (1.6%) were caused by HBV, 5 (2.8%) were caused by
dual HBV/HCV coinfection, and 12 (6.6%) were caused by
triple HBV/HCV/hepatitis D virus coinfection [16]. Alcohol
consumption, signiﬁcantly associated with a diagnosis of
cirrhosis, was found to be more frequent among patients
with chronic viral hepatitis compared to patients without
these coinfections (P<0.001). Interestingly, alcohol was not
found to be the only cause of cirrhosis in any one patient
[16].Asidefromhighalcoholconsumption,coinfectionwith
HCVand/orHBVareriskfactorsfordevelopinglivertoxicity
(OR 10.36, 95% CI 1.38–77.56, P = 0.03) [17].
3.1.3. Alcohol-Induced Inﬂammation Leads to Progression
of HIV and Other Comorbid Reactions. Many processes
related to the consumption or breakdown of alcohol thatAIDS Research and Treatment 5
contribute to alcohol-induced liver disease are mediated by
small proteins known as cytokines, which are produced and
secreted by liver cells and many other cells throughout the
body [18]. Through a variety of actions, cytokines regulate
certain biochemical processes in the cells that produce them,
as well as in neighbouring cells. For example, in the case of
HIV infection, they attract white blood cells to the tissue,
triggering an inﬂammatory response. In the liver, persistent
cytokine secretion resulting in chronic inﬂammation leads to
conditions such as hepatitis, ﬁbrosis and cirrhosis. Cytokines
also regulate a process known as programmed cell death, or
apoptosis, which is in part responsible for alcohol-induced
loss of liver tissue [19].
Dyslipidemia, consisting of hypertriglyceridemia, low
high-density lipoprotein (HDL) cholesterol, and elevated
low-density lipoprotein (LDL) cholesterol, is being observed
with increasing frequency among persons living with HIV.
Hazardous alcohol consumption, particularly among His-
panic individuals and in individuals consuming the highest
amounts of alcohol, worsens dyslipidemia [20].
Alcohol use and not being on HAART (P<0.001) are
independentpredictorsofpneumoniainHIVpositivesmok-
ers [21]. The incidence of pneumonia was signiﬁcantly lower
in the HAART era compared to the pre-HAART era (P<
0.01), although alcohol abuse remains an independent risk
factor for developing bacteremic pneumococcal disease [22].
Cerebrovascular ischemia was associated with a history
of high alcohol intake, and fewer months on HAART (OR
0.97, 95% CI 0.96–0.99; P<0.001). This suggests that long-
term HAART has a protective eﬀect against cerebrovascular
ischemia, yet this eﬀect is countered by a history of alcohol
abuse [23].
A history of alcohol abuse or dependence was not
associated with neuropathic pain caused by HIV-associated
sensory neuropathy [24].
Signiﬁcant diﬀerences were found between HIV positive
heavy drinkers and HIV-negative light drinkers with respect
to motor and visuomotor speed, pointing to a synergistic
interaction between alcohol abuse and HIV infection [25].
Impaired upper limb function was observed between
clinical groups (HIV positive patients, patients with alco-
holism, and patients with HIV infection and alcoholism
comorbidity) and controls in terms of upper motor compos-
ite score (P = 0.008 for HIV group, P = 0.031 for alcoholism
groups and P = 0.003 for HIV and alcoholism comorbidity
group) and slower ﬁne ﬁnger movement (P = 0.004 for HIV
group, P = 0.033 for alcoholism groups and P = 0.0003 for
HIV and alcoholism comorbidity group) [26]. Although not
signiﬁcant, HIV and alcoholism comorbidity impair upper
motor limb function to a greater degree that HIV alone or
alcoholism alone. There were signiﬁcant diﬀerences between
groups with respect to closed eye composite scores (stand
heel-to-toe, walk heel-to-toe, and stand on one leg with eyes
closedtasks)(P = 0.013)[26].Thesediﬀerencescouldnotbe
explained by the presence of peripheral neuropathy, HAART,
or AIDS-deﬁning events [26].
Immediate episodic memory was found to be impaired
in HIV positive patients suﬀering from alcoholism, com-
pared to either HIV positive patients without a drinking
problem, HIV-negative patients suﬀering from alcoholism
or normal controls [27]. Interestingly, these results could
not be explained by the amount of alcohol consumed over
a lifetime, CD4+ cell counts, AIDS diagnosis, or HAART
medication. HIV infection or alcoholism alone did not aﬀect
immediate episodic memory. Also, working memory and the
ability to retain information over time were not impaired by
HIV infection or alcoholism [27].
Alcohol abuse was not associated with a longer time
before clinical stability was achieved among patients who
developed bacterial community-acquired pneumonia [28].
3.1.4. Nonalcoholic Steatohepatitis and HIV Disease Progres-
sion. While alcohol abuse is generally associated with HIV
diseaseprogression,severalstudiesdidnotﬁndsuchanasso-
ciation. For example, Crum-Cianﬂone et al. [29] found that
the most common diagnosis among HIV positive patients
with liver test abnormalities was that of non-alcoholic fatty
liver disease. The amount of alcohol consumed per week and
alcohol abuse were not predictors of liver test abnormalities.
The low number of patients suﬀering from viral hepatitis
coinfection was not high enough to uncover any eﬀect of
these comorbidities. While ART use overall did not predict
liver test abnormalities, the use of protease inhibitors did
(P = 0.04) [29]. A separate study found that alcohol
consumption was not associated with HCV-related serious
adverse reactions in a cohort of 1175 HIV-infected patients
(1048 (89.2%) were HCV coinfected) [30].
3.1.5. Injecting Drug Users and HIV. Compared to healthy
noninjecting drug users (IDU), HIV patients who were
not alcohol abusers (control population), HIV IDU only,
HIV alcohol abusers, and IDU alone were each signiﬁcantly
associated with a lower level of CD4+ lymphocyte recovery
(P<0.04) [31]. However, no such association was found
with respect to alcohol abuse alone. Compared to patients
who did not abuse either alcohol or injectable drugs, no
signiﬁcant diﬀerences in terms of virological response (i.e.,
undetectable viral load) were found for either of the three
study groups [31]. Unfortunately, the eﬀects of alcohol
consumption on HAART adherence are not analyzed in this
study [31].
3.2. The Role of Alcohol Consumption on the Immune System
and the HIV Viral Load. Table 2 presents some recent data
on the role played by alcohol on CD4+ cell counts and the
plasma viral load.
Alcohol abuse after contacting HIV seems to accelerate
disease progression through a direct eﬀect on CD4+ cells. Of
note is the detrimental role played by alcohol consumption
on CD4+ cell counts, particularly among individuals not on
ART [32–36]. Heavy alcohol consumption is associated with
a four times lower chance of achieving undetectable viral
load and a two times higher chance of having low CD4+
cell counts, compared to moderate alcohol consumption or
abstinence [33]. Alcohol is an immunosuppressant acting
directly through T-cell apoptosis, mitochondrial damage,
and inhibition of T-cell responses, natural killer cell activity6 AIDS Research and Treatment
Table 2: The Role of Alcohol on the Immune System and the HIV Viral Load.
Ref. Study
settings Population characteristics Alcohol use patterns Main ﬁndings
[33]U S A 220 HIV-1-infected IDUs receiving
HAART
Heavy alcohol consumption (daily or 3-4
times per/week) reported in 139 (63.2%)
patients.
Men (OR 2.6, 95% CI 1.13–5.99,
P = 0.013) and participants between 35
and 45 years of age more likely to be
heavy alcohol users (P = 0.006)
Heavy alcohol consumption associated
with 4 times lower chance of achieving
undetectable viral load and 2 times higher
chance of having a CD4+ cell count of
<500 cells/µL, compared to moderate
alcohol consumption or abstinence
[34] USA 595 HIV positive patients 245 (41.2%) subjects consumed alcohol
Heavy alcohol consumption associated
with lower CD4+ cell counts only among
subjects not on ART (P = 0.03)
[35] USA 231 HIV positive drug users
126 (54.5%) participants consumed
alcohol There were 53 (22.9%) frequent
alcohol users (≥2 alcoholic drinks daily).
No diﬀerences in alcohol consumption
between patients on ART and patients
not on ART
Frequent alcohol use (≥2 drinks/day)
associated with CD4+ cell counts ≤200
cells/µL (OR 2.907, 95% CI 1.233–6.855,
P = 0.015).
Frequent alcohol intake associated with
higher viral load over time (P = 0.038)
[36] USA 391 HIV positive patients
154 (39.4%) report past week alcohol
consumption with mean number of 4
drinks
62 (15.8%) consumed >5 drinks/week
Consuming >5 drinks/week predictor for
unsuppressed viral load (≥400 copies/mL)
(OR 4.2, 95% CI 1.1–18.5, P = 0.046)
[38]U S A 2056 HIV-infected women and 569
HIV-uninfected women
33.6% of HIV positive women consumed
≥8 drinks/week 51.8% of HIV positive
women consumed 1–7 drinks/week
Consuming ≥8 drinks/week related to
higher risk of death (OR 3.39, 95% CI
1.54–7.44, P<0.002)
[39] USA 2702 HIV positive patients
Individuals were categorized as
nondrinkers (no alcohol consumption),
hazardous drinkers (consume ≥5
standard drinks on drinking days), and
nonhazardous drinkers (consume <5
standard drinks on drinking days)
Nonhazardous alcohol consumption
decreased survival by >1 year if frequency
of consumption was ≥1/week, and by 3.3
years with daily consumption (from 21.7
years to 18.4 years).
Hazardous alcohol consumption decreased
o v e r a l ls u r v i v a lb y>3 years if frequency of
consumption was ≥1/week, and by 6.4
years with daily consumption (from 16.1
years to 9.7 years)
and macrophage phagocytic activity. Alcohol consump-
tion may increase susceptibility to opportunistic infections
and accelerate disease progression among HIV positive
individuals. Additionally, alcohol leads to impaired viral
load response and reduced CD4+ cell reconstitution [35].
Frequent alcohol use is signiﬁcantly associated with low
CD4+ cell counts and higher viral loads over time [35].
In patients not on ART, heavy alcohol consumption was
associated with lower CD4+ cell counts compared to patients
with a history of abstinence. At-risk drinkers (4 drinks/week
for women and 5 drinks/week for men) were less likely to
have a current HAART prescription (P<0.05) and were
less likely to have suppressed viremia if they had a current
HAART prescription (P<0.05), compared to nondrinkers
[36]. Consuming more than 5 drinks/week is a predictor
for not being on HAART and for having an unsuppressed
viralload[36].Moreover,theriskofopportunistic infections
increases as CD4+ cell counts decline.
The type of alcohol being consumed is important with
regards to outcome in HIV positive patients currently taking
HAART [37]. In subjects consuming only beer or wine,
increases in thymus size and in CD4+ cell counts were
observedfollowingHAARTinitiation.Incontrast,consump-
tion of only liquor was associated with decreases in both
thymus size and in CD4+ cell counts, particularly evident
in women. M´ ıguez-Burbano et al. [37] conclude that liquor
consumption is associated with thymus deterioration and
poor virologic and immunologic control in HIV positive
patients taking ART.
Moderate alcohol use (<1 drink per day for the past
6 months) did not signiﬁcantly increase the rate in CD4+
cell count decline to ≤200 cells/µL, compared to abstainers.
Frequent alcohol use (>2 drinks/day) resulted in a risk of
CD4+ cell counts decline that was almost three times higher
than that for moderate alcohol use. CD4+ cell counts decline
w a sf a s t e ri nf r e q u e n ta l c o h o lu s e r sw h ow e r en o to nA R T
than in those who were on ART [34, 35]. CD4+ cell counts
decline was faster in frequent alcohol users who combined
alcohol with crack cocaine. Viral load was found to be
0.259 log10 units higher in frequent alcohol users than in
moderate alcohol users and abstainers. This relationship was
found to be signiﬁcant in patients who were receiving ART.AIDS Research and Treatment 7
Alcohol use had no impact on HIV viral loads in patients not
receiving ART. One possible explanation for these ﬁndings
in that heavy alcohol use is deleterious in patients on ART
because it might decrease patient adherence to ART, rather
than alcohol having a direct eﬀect on viral load [34, 35].
Ad r o pi nC D 4 + cell counts is mediated by the direct toxic
eﬀect of alcohol on these lymphocytes, which appears to be
independent of the viral load. At the same time, Samet et
al. [34] argue that the beneﬁcial eﬀect of ART on CD4+ cell
counts may account for a lower toxicity seen when alcohol is
abused in the presence of ART.
Consuming ≥8 alcoholic drinks/week was related to a
higherriskofdeath[38].Infact,Braithwaiteetal.[39]found
that alcohol consumption of any kind decreases survival in
HIV positive patients.
3.3. The Role of Alcohol Consumption on Medication Adher-
ence. Drug and/or alcohol abuse and suboptimal ART
adherence are predictors of virological failure [40]. Table 3
presents studies in which alcohol consumption modulates
medication adherence.
Following the introduction of HAART in 1996, indi-
viduals living with HIV taking this form of medication
have beneﬁted from improvements in immunological and
virological parameters, as well as an improved quality of live
and longevity [41]. However, adherence to HAART in excess
of 95% is often regarded as optimal in order to beneﬁt from
this treatment [41].
3.3.1. Alcohol Consumption and Nonadherence to ART. Nu-
merous studies from around the world document the det-
rimental eﬀect of alcohol on HAART adherence, from the
United States [36, 42–55], to Europe [56–61], Australia [62],
Africa [63–69], South America [70, 71], and Asia [72,
73]. Alcohol consumption is associated with the ﬁrst non-
structured treatment interruption, early (within the ﬁrst
year) versus late treatment interruption, and interruption of
longer duration (≥6 months) [53, 66].
In addition to nonadherence, at-risk drinkers were less
likely to have a current HAART prescription. As a result,
at-risk drinking was a predictor of not being on HAART
[36, 51]. In fact, all levels of drinking were associated with
higher odds of not using HAART compared to alcohol
abstinence [54], such that dose-dependent worsening of
adherence was found with increasing alcohol consumption
[49, 54, 60]. The highest degree of nonadherence was found
in cases where alcohol use was classiﬁed as problem drinking
(deﬁned as meeting NIAAA criteria for at-risk drinking or
diagnostic criteria for an alcohol use disorder) (OR 0.474,
95%CI0.408–0.550),whileitwaslowerinstudiesexamining
any or global alcohol use (OR 0.604, 95% CI 0.531–0.687)
[41]. In the combined analysis of 40 studies reviewed in a
meta-analysis, alcohol drinkers were approximately 50–60%
as likely to be classiﬁed as adherent (OR 0.548, 95% CI
0.490–0.612) compared with abstainers (or those who drank
relatively less) [41].
Concurrent crack cocaine use is associated with even
lower adherence (OR 3.61, 95% CI 1.56–8.35, P<0.01) [51],
as is a lifetime history of being an IDU (OR 2.17, 95% CI
1.16–4.05, P = 0.015) [70].
Nonadherence is often associated with unsuppressed
viremia. For example, Shacham et al. [36] found that con-
suming more than 5 drinks/week is a predictor for having an
unsuppressed viral load.
The reasons behind the association between alcohol
consumption and nonadherence are varied. For example,
due to the belief that alcohol should not be mixed with their
medication, people living with HIV/AIDS may interrupt
their medication when they are drinking [52] or delay HIV
treatment while trying to cope with alcohol dependence
[64]. Forgetfulness does seem to play an important role, as
substance use by the caregiver was associated with higher
odds of ART nonadherence among children in their care [42,
65]. Alcohol also appears to aﬀect adherence to ART through
conscious decisions to skip medication while drinking and
not through drunken forgetfulness [45]. Based on their
research, Sankar et al. [45] found that light drinkers are the
most likely subgroup to miss medication.
3.3.2. Other Factors Linked to Nonadherence. Drinking pat-
t e r n sw e r ef o u n dt od i ﬀer across gender and ethnic groups.
For example, hazardous drinking was more predominant
among African-American (P<0.01) and mixed race (P<
0.04) patients, compared to white patients, and African
American patients were less likely to report 100% adherence
(OR 0.35, 95% CI 0.17–0.71, P<0.01) [55]. Afrodescent
was marginally associated with poor adherence in a Brazilian
study as well (OR 1.55, 95% CI 0.97–2.47, P = 0.068) [70].
The detrimental eﬀects of alcohol on medication adherence
seem to aﬀect women to a greater degree than men [44, 50].
Several other factors are also related to nonadherence.
Each additional year of life was associated with further
decrease in adherence (OR 0.96, 95% CI 0.92–1.00, P<
0.04), while a higher level of medication-speciﬁc social
support (e.g., companionship or assistance) diminished the
negative eﬀects of alcohol consumption on ART adherence
(OR 1.06, 95% CI 1.01–1.12, P = 0.01) [55].
Signiﬁcance of alcohol consumption diminishes once
stress is factored in, suggesting that life stress may be one of
the main causes for alcohol and drug consumption in HIV
positive individuals, and alcohol consumption may in turn
lead to nonadherence [47].
An interesting observation reported in a South African
study is that many participants refused to disclose their HIV
status to their family out of fear that their family would
consume alcohol as result of such news, highlighting the
wide-spread alcohol consumption in some communities
[63].
Based on ﬁndings from these studies, it is recommended
that HIV treatment programs address at-risk drinking as
well [51]. The clinical evaluation of a person living with
HIV should also determine the prevalence of alcohol use
and/or the presence of alcohol use disorders. Moreover, an
assessment of concomitant drug and alcohol use, as well as
comorbidities, is needed in both men and women.
There have also been reports of no association between
alcohol consumption and delayed HAART initiation [74],8 AIDS Research and Treatment
Table 3: Alcohol Consumption and Nonadherence to ART.
Ref. Study
settings Population characteristics Alcohol use patterns Main ﬁndings
Found Nonadherence
[36] USA 391 HIV positive patients
154 (39.4%) report past week alcohol
consumption, for a mean number of 4
drinks
At-risk drinkers (4 drinks/week for women
and 5 drinks/week for men) are less likely
to have current HAART prescription
(P<0.05).
At-risk drinking a predictor for not being
on HAART (P = 0.025)
[40] USA 1074 HIV positive patients
315 (29.4%) patients presented with
current or past history of drugs and/or
alcohol abuse
Current or past history of drugs and/or
alcohol abuse (OR 2.10, 95% CI 1.32–3.35,
P = 0.002) and suboptimal adherence (OR
2.84, 95% CI 1.77–4.55, P<0.001)
predictors for virological failure
[42] USA 43 HIV positive children Alcohol abused by caregiver
Substance use by the caregiver associated
with having higher viral loads in children
patients (P = 0.007)
[43]U S A
197 HIV-infected
individuals with history of
alcohol problems who were
receiving HAART
79 (40.1%) use alcohol
HIV positive drinkers less adherent to
HAART than HIV positive alcohol
abstainers (P<0.05)
[44] USA 1944 HIV positive patients
55% of 640 men and 28% of 1304 women
consumed low levels of alcohol
15% of men and 8% of women
consumed high levels of alcohol
7% of men and 4% of women engaged in
binge drinking
Binge drinking (OR 1.75, 95% CI
1.17–2.64, P ≤ 0.05), moderate-to-heavy
alcohol consumption (OR 1.47, 95% CI
1.08–1.99, P ≤ 0.05) and low alcohol
consumption (OR 1.28, 95% CI 1.05–1.54,
P ≤ 0.05) associated with nonadherence
for women only
[45]U S A82 HIV positive
African-American patients
Alcohol can aﬀect ART adherence through
conscious decisions to skip medication
while drinking and not through drunken
forgetfulness
[46] USA 5887 HIV positive patients
3573 (60.7%) respondents report alcohol
use in past 12 months
630 (17.6%) alcohol users were
nonadherent
Alcohol use in past 12 months associated
with nonadherence (OR 1.3, 95% CI
1.1–1.5, P<0.05)
[47]U S A
105 HIV positive patients
without alcohol
dependence
Mean monthly alcohol consumption was
4.64 ±8.00 drinks/person
Monthly alcohol consumption associated
with missed medication in the past 2 weeks
(OR 1.08, CI 1.02–1.15, P<0.01) and over
the past weekend (OR 1.09, CI 1.03–1.15,
P<0.01)
47 (44.8%) patients missed a medication
dose in the past 2 weeks, and 23 (21.9%)
missed medication during the previous
weekend
[48]U S A
275 HIV positive patients
with alcohol use disorders
154 (56.0%) patients were
nonadherent
An average of 84.9 standard drinks over
the thirty days prior to the baseline
interview
Alcohol consumption (P = 0.001) and
number of drinks (P = 0.002) related to
nonadherence
[49] USA 1671 HIV positive women 60% of sample were abstainers and 26%
were light drinkers (<3 drinks/week)
Light drinking (<3 drinks/week) (OR 1.51,
CI 1.30–1.76, P<0.01), moderate
drinking (3–13 drinks/week) (OR 2.46, CI
1.96–3.09, P<0.01), and heavy drinking
(OR 4.37, CI 2.99–6.40, P<0.01)
associated with self-reported ART
nonadherence
[50] USA 67 HIV positive patients
Alcohol dependence is a speciﬁc and
signiﬁcant predictor of ART nonadherence
in women only (P<0.05)AIDS Research and Treatment 9
Table 3: Continued.
Ref. Study
settings Population characteristics Alcohol use patterns Main ﬁndings
[51] USA 643 HIV positive IDUs
Fewer at-risk drinkers that nondrinkers
reported receiving ART (OR 1.19, 95% CI
0.59–2.42)
[52] USA 145 HIV positive patients
60 (41.4%) participants were current
drinkers
11 participants (18% of drinkers) were
problem drinkers (AUDIT score ≥8)
1 in 4 drinkers report stopping medication
while consuming alcohol
Alcohol use predicted treatment
nonadherence (P<0.05)
[53] USA 335 HIV positive IDUs
Heavy alcohol use associated with ﬁrst
nonstructured treatment interruption (OR
1.58, 95% CI 0.92–2.70), early (within the
ﬁrst year) versus late treatment
interruption (OR 1.55, 95% CI 0.51–4.73),
and interruption of longer duration (≥6
months) (OR 3.21, 95% CI 0.83–12.5)
[54]U S A
1354 HIV positive women
for whom HAART was
indicated
Light drinking (OR 1.39, 95% CI
1.03–1.89, P ≤ 0.05), moderate drinking
(OR 1.72, 95% CI 1.10–2.70, P ≤ 0.05)
and heavy drinking (OR 2.29, 95% CI
0.96–5.47) associated with nonadherence,
compared to nondrinking
[55] USA 224 HIV positive patients
Baseline prevalence of past year
hazardous drinking was 27% (AUDIT
score ≥8)
Hazardous drinking associated with
nonadherence
[56] France 445 HIV positive patients
329 (73.9%) patients consumed ≤1 unit
of alcohol/day at baseline
116 (26.1%) patients consumed >1 unit
of alcohol/day at baseline
Baseline alcohol consumption associated
with nonsigniﬁcant nonadherence after 4
months (P = 0.09)
[57] France 276 HIV positive IDUs
receiving HAART
Approximately 84% of patients report
alcohol consumption during the past 6
months
Monthly alcohol consumption during past
6 months associated with ART
nonadherence (OR 1.15, CI 1.08–1.23,
P<0.001)
[58] France 1010 HIV positive patients 59 (5.8%) patients report daily alcohol
consumption
Nonadherence more common among
subjects who consume alcohol daily (OR
0.39, CI 0.20–0.58, P<0.001)
[59] France
2340 HIV positive patients
receiving HAART.
Harmful alcohol
consumption was frequent
12% of patients had symptoms of
potential alcohol abuse/dependence
d u r i n gt h ep r e v i o u s1 2m o n t h s( C A G E
questionnaire score of ≥2)
27% of patients suﬀered from hazardous
drinking or alcohol use disorders
(AUDIT-C questionnaire score of >4f o r
women and >5f o rm e n )
9% of patients reported regular binge
drinking (≥6 alcohol units drunk
consecutively at least twice a month)
Harmful alcohol consumption associated
with nonadherence to HAART (P<0.001)
for regular binge drinking and symptoms
of alcohol abuse or dependence
[60] Switzerland 6709 HIV positive patients
Increasing alcohol intake associated with
deteriorating adherence to ART (OR 1.25,
95% CI 1.10–1.43)
[61] Sweden 946 HIV positive patients 15.5% of patients report alcohol and drug
problems
Adherent patients more likely not to have
problems with alcohol (OR 1.8, 95% CI 9
1.18–3.01, P = 0.008)
[62] Australia
1106 HIV-infected patients
867 (78.4%) report taking
cART, 339
(39.1%) of which report
diﬃculty adhering to
medication
Alcohol use associated with self-reported
nonadherence (OR 1.47, 95% CI
1.03–2.09, P<0.05)10 AIDS Research and Treatment
Table 3: Continued.
Ref. Study
settings Population characteristics Alcohol use patterns Main ﬁndings
[63] South
Africa
12 HIV positive patients
receiving HAART
Alcohol abuse identiﬁed as barrier to
adherence
[64] South
Africa
8m a l eH I Vp o s i t i v e
patients
Patients delay HIV treatment while coping
with alcohol dependence
[65] South
Africa 56 HIV positive children
Alcohol use by caregiver associated with
poorer ART adherence in children patients
(P<0.01)
[66] Cameroon 533 HIV positive patients 60 (11.3%) patients reported binge
drinking
Binge drinking associated with
interruption of ART
[67] Ethiopia 422 HIV positive patients
31 (7.3%) subjects report alcohol
consumption, 6 of which did so on a
regular basis
Alcohol drinking associated with
nonadherence (OR 0.210, CI 0.071–0.617,
P = 0.003)
[68]B o t s w a n a300 adult HIV positive
patients
Alcohol use predicted poor ART adherence
(P<0.02)
[69]
Benin, Cˆ ote
d’Ivoire,
and Mali
2920 HIV positive patients
Current drinking (OR 1.4, 95% CI
1.1–2.0), especially hazardous drinking
(OR 4.7, 95% CI 2.6–8.6), associated with
nonadherence
[70] Brazil 306 HIV positive patients 37.6% of sample consumed alcohol in
month prior to baseline interview
ART nonadherence associated with alcohol
use in month before baseline interview
(OR 1.61, 95% CI 1.08–2.39, P = 0.018)
[71] Brazil 295 HIV positive patients 109 (37.3%) subjects consumed alcohol
in month prior to baseline interview
Nonadherence to ART associated with
alcohol use (P<0.001)
[72] Thailand 205 HIV positive patients 13 (6.3%) subjects report current alcohol
use
Current alcohol use sole predictor of
nonadherence to HAART (OR 1.67, CI
1.05–2.48, P<0.001)
[73] India 198 HIV-infected patients
receiving HAART
Alcohol use associated with nonadherence
(OR 5.68, 95% CI 2.10–15.32, P = 0.001)
Did Not Find Nonadherence
[74] USA 1030 HIV-infected women No delay in ART initiation between heavy
drinkers and nondrinkers
[75]U S A300 HIV positive men who
have sex with men
43% of sample report alcohol
consumption in ﬁrst 2 weeks
post-baseline
No association found between alcohol use
and nonadherence
[76] UK 394 HIV positive patients
Excessive alcohol consumption borderline
signiﬁcantly lower in patients receiving
HAART (P<0.08)
[77] Uganda
2311 HIV positive patients
928 (40.2%) presented late
for treatment
123 (5.3%) used moderate levels of
alcohol and 360 (15.5%) used high levels
of alcohol
Alcohol consumption in past year
(assessed using AUDIT-C) negatively
associated with late presentation for
treatment (OR 0.65, 95% CI 0.44–0.96,
P = 0.03 for moderate use and OR 0.79,
95% CI 0.61–1.00, P = 0.05 for heavy use)
HAART administration [29], and nonadherence [75], and
even lower alcohol consumption among individuals receiv-
ing HAART [76] and earlier presentation for HAART in-
itiation among patients consuming alcohol [77]. However,
while important, such reports are relatively rare, and there
is an overall considerable and consistent association between
alcohol consumption and medication nonadherence [41].
3.3.3. ART Adherence and the Development of Class-Speciﬁc
Medication Resistance. The association between ART adher-
ence and the development of class-speciﬁc ART resistance
represents a clinical problem. During multidrug therapy,
diﬀerential drug exposure increases the likelihood of devel-
oping resistance. In addition, ART with higher potency and
higher genetic barriers to resistance decrease the incidenceAIDS Research and Treatment 11
of resistance for companion ART at all adherence levels.
Drug resistance mutations proliferate under conditions of
nonsuppressive ART, which is usually the result of inade-
quate drug exposure [78]. As poor adherence is the major
determinant of inadequate drug exposure, ART adherence
is critically linked to the development of medication resis-
tance. In low-income countries such as South Africa where
alcohol consumption is very high, nonadherence is more
often producing resistance mutations, therefore leading to
inadequate suppression of the HIV virus. The present review
concords with the systematic review of Shuper et al. [79],
bringing evidence that alcohol aﬀects the immune system,
consequently contributing to a deteriorating course of HIV
disease. In addition, alcohol misuse impacts on medication
adherence.
4. Conclusions
The primary goal of ART is to increase disease-free survival
through suppression of viral replication and improvement
in immunological function. The optimal time to initiate
treatment is inﬂuenced by these known beneﬁts and the risk
of drug toxicity, potential emergence of viral drug resistance,
and the need for lifetime therapy. The complexities of
adherence-resistance relationships are related to character-
istics of the virus, the medication, misuse of alcohol, and
their interactions. Nevertheless, the eﬀectiveness of ART can
be limited by lack of access to therapy. Additionally, a set
of acquired behaviour, such as alcohol misuse and poor
adherence and/or intolerance, can lead to ART resistance.
Therefore, especially in low-income populations, the educa-
tion of individuals who live with HIV and alcohol abuse is
relevant.
Knowledge of class-speciﬁc adherence-resistance rela-
tionships may help clinicians and patients tailor therapy
to match individual patterns of adherence in order to
minimize the development of resistance and treatment
failure. In addition, in low-income settings, this information
may guide the selection of optimal drug combinations and
regimen sequences to improve the durability of ART. More-
o v e r ,a l c o h o lu s ea n da l c o h o ld e p e n d e n c ea r ew i d e s p r e a di n
the general population. Many people suﬀering from alcohol
use disorders also suﬀer from other psychiatric disorders
including drug abuse disorders. Importantly, persons living
with HIV should be assessed not only for their immunologic
and virologic statuses, but also for comorbidities.
This is particularly important but rarely assessed or/and
reported in the literature. Modeling or condition simulation
may introduce these interactions in the context of the
corresponding topic leading to possible interventions.
Animportantobjectiveofourstudyistobringawareness
of these complex interactions in the medical and educa-
tion ﬁelds. Awareness should lead to cooperation between
patients living with HIV, their caregivers, and researchers
looking into the mechanism of relationship between the
virus, disease progression, alcohol, and its comorbidities.
Multiplesubstancesofmisuse,suchascombinedalcoholand
cocaine, might be associated with behaviour and metabolic
consequences not measured or not considered in these
analyses. These drug-induced biological phenomena may
promote disease progression and CD4+ cell loss, as well as
poor adherence with prescribed medication and/or inad-
equate micronutrient and macronutrient intake. Because
the patterns of substance abuse observed in these HIV
positive cohorts might not be common or typical of other
HIV populations, these ﬁndings can be generalized only
to other infected populations with similar patterns of sub-
stance abuse. Further studies targeting HIV heavy alcohol
users, that control for other confounding behavioural and
metabolic variables, need to be conducted to conﬁrm and
extend the knowledge in this area. Moreover, a network
of direct discussion is needed between people living with
HIV/AIDS, medical personnel treating HIV and/or addic-
tions, epidemiology researchers, as well as policy makers and
treatment planners.
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